NASDAQ:HUMA Humacyte (HUMA) Stock Price, News & Analysis → the most reliable asset on earth is making a comeback (From DTI) (Ad) Free HUMA Stock Alerts $3.09 -0.01 (-0.32%) (As of 09:34 AM ET) Add Compare Share Share Today's Range$3.06▼$3.1450-Day Range$2.59▼$4.8452-Week Range$1.96▼$5.60Volume32,552 shsAverage Volume926,247 shsMarket Capitalization$361.10 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Humacyte alerts: Email Address Humacyte MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.75 Rating ScoreUpside/Downside158.1% Upside$8.00 Price TargetShort InterestHealthy4.47% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.54Based on 17 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.95) to ($0.64) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.09 out of 5 starsMedical Sector373rd out of 939 stocksBiotechnology Industry4th out of 19 stocks 3.4 Analyst's Opinion Consensus RatingHumacyte has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Humacyte has a forecasted upside of 158.1% from its current price of $3.10.Amount of Analyst CoverageHumacyte has only been the subject of 2 research reports in the past 90 days. Previous Next 4.0 Short Interest Percentage of Shares Shorted4.47% of the float of Humacyte has been sold short.Short Interest Ratio / Days to CoverHumacyte has a short interest ratio ("days to cover") of 4.3.Change versus previous monthShort interest in Humacyte has recently decreased by 36.47%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldHumacyte does not currently pay a dividend.Dividend GrowthHumacyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for HUMA. Previous Next 3.1 News and Social Media Coverage News SentimentHumacyte has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Humacyte this week, compared to 2 articles on an average week.Search Interest13 people have searched for HUMA on MarketBeat in the last 30 days. This is an increase of 86% compared to the previous 30 days.MarketBeat Follows13 people have added Humacyte to their MarketBeat watchlist in the last 30 days. This is an increase of 225% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Humacyte insiders have not sold or bought any company stock.Percentage Held by Insiders23.10% of the stock of Humacyte is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions44.71% of the stock of Humacyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Humacyte are expected to grow in the coming year, from ($0.95) to ($0.64) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Humacyte is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Humacyte is -2.90, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHumacyte has a P/B Ratio of 2.74. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIthe most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.And you can see how it works for FREE when you Click Here About Humacyte Stock (NASDAQ:HUMA)Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs). Its investigational HAVs are designed to be easily implanted into any patient without inducing a foreign body response or leading to immune rejection. The company is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; and coronary artery bypass grafting, as well as developing its HAVs for pediatric heart surgery and cellular therapy delivery, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina.Read More HUMA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HUMA Stock News HeadlinesMarch 27, 2024 | americanbankingnews.comHumacyte (NASDAQ:HUMA) Receives "Neutral" Rating from Piper SandlerMarch 26, 2024 | globenewswire.comHumacyte to Host Virtual KOL Event “Hemodialysis Access: A Crossroads of Care,” on March 28, 2024March 28, 2024 | DTI (Ad)CBOE shift unlocks new weekend income strategyYou might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange. You're probably wondering, “Okay… But how does that affect me?” This perk now allows everyday traders like yourself to target extra income over the weekend. March 26, 2024 | americanbankingnews.comHumacyte (NASDAQ:HUMA) Receives Buy Rating from BenchmarkMarch 23, 2024 | markets.businessinsider.comHumacyte’s Strong Outlook: Buy Rating Affirmed Amid Advancements and Market OpportunityMarch 23, 2024 | finance.yahoo.comQ4 2023 Humacyte Inc Earnings CallMarch 22, 2024 | markets.businessinsider.comBuy Rating for Humacyte: Anticipated FDA Approval and Strong Financials Signal Growth PotentialMarch 22, 2024 | investorplace.comHUMA Stock Earnings: Humacyte Meets EPS for Q4 2023March 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.March 22, 2024 | msn.comHumacyte GAAP EPS of -$0.24 in-lineMarch 22, 2024 | globenewswire.comHumacyte Fourth Quarter and Year End 2023 Financial Results and Business UpdateMarch 21, 2024 | markets.businessinsider.comWhat Wall Street expects from Humacyte's earningsMarch 20, 2024 | americanbankingnews.comHumacyte (HUMA) Scheduled to Post Quarterly Earnings on FridayMarch 18, 2024 | globenewswire.comHumacyte to Present 2023 Fourth Quarter and Year-End Financial Results and Provide Corporate Update on March 22, 2024March 18, 2024 | ca.finance.yahoo.comHUMA Apr 2024 5.000 callMarch 4, 2024 | marketwatch.comHumacyte Shares Rise 10% on Common Stock OfferingMarch 1, 2024 | msn.comWhy Humacyte (HUMA) Shares Are FallingMarch 1, 2024 | globenewswire.comHumacyte, Inc. to Present at the TD Cowen 44th Annual Health Care ConferenceMarch 1, 2024 | msn.comHumacyte stock dips after pricing stock offering to raise $40.2MFebruary 29, 2024 | marketwatch.comHumacyte Shares Drop 19% After Proposed Public Offering NewsFebruary 29, 2024 | globenewswire.comHumacyte, Inc. Announces Pricing of $40.2 Million Public Offering of Common StockFebruary 29, 2024 | globenewswire.comHumacyte, Inc. Announces Proposed Public Offering of Common StockFebruary 26, 2024 | finance.yahoo.comHere's Why We're Watching Humacyte's (NASDAQ:HUMA) Cash Burn SituationFebruary 23, 2024 | finance.yahoo.comBCTX Jul 2024 2.500 putFebruary 17, 2024 | finance.yahoo.comIMGN Mar 2024 32.000 put(CONTRAFebruary 17, 2024 | finance.yahoo.comHUMA Mar 2024 5.000 putFebruary 15, 2024 | finance.yahoo.comIMGN Jul 2024 29.000 callSee More Headlines Receive HUMA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Humacyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/22/2024Today3/28/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:HUMA CUSIPN/A CIK1818382 Webwww.constellationalpha.com Phone919-313-9633FaxN/AEmployees164Year FoundedN/APrice Target and Rating Average Stock Price Target$8.00 High Stock Price Target$15.00 Low Stock Price Target$4.00 Potential Upside/Downside+158.9%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-110,780,000.00 Net MarginsN/A Pretax Margin-286,051.62% Return on Equity-160.98% Return on Assets-57.90% Debt Debt-to-Equity Ratio0.46 Current Ratio6.79 Quick Ratio6.79 Sales & Book Value Annual Sales$1.57 million Price / Sales230.00 Cash FlowN/A Price / Cash FlowN/A Book Value$1.13 per share Price / Book2.73Miscellaneous Outstanding Shares116,860,000Free Float89,866,000Market Cap$361.10 million OptionableOptionable Beta1.53 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Laura E. Niklason M.D. (Age 61)Ph.D., Founder, President, CEO & Director Comp: $717.85kMr. Dale A. Sander (Age 64)CFO, Chief Corporate Development Officer & Treasurer Comp: $667.45kDr. Shamik J. Parikh M.D. (Age 51)Chief Medical Officer Comp: $514.72kDr. Juliana L. Blum Ph.D.Co-Founder & Executive AdvisorDr. Heather Ledbetter Prichard Ph.D. (Age 46)Chief Operating Officer Comp: $576.44kMs. Sabrina OsborneExecutive Vice President of Business Strategy & PeopleMr. William John Scheessele (Age 52)Chief Commercial Officer Mr. Harold AltersonSenior Vice President of QualityDr. Yang Cao M.D. (Age 58)Ph.D., Chief Regulatory Officer More ExecutivesKey CompetitorsKodiak SciencesNASDAQ:KODProKidneyNASDAQ:PROKTenaya TherapeuticsNASDAQ:TNYATScan TherapeuticsNASDAQ:TCRXMonte Rosa TherapeuticsNASDAQ:GLUEView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 104,299 shares on 3/11/2024Ownership: 3.016%Goldman Sachs Group Inc.Sold 31,824 shares on 3/1/2024Ownership: 0.097%GSA Capital Partners LLPBought 81,163 shares on 2/16/2024Ownership: 0.422%Citadel Advisors LLCSold 12,500 shares on 2/15/2024Ownership: 0.000%Wolverine Trading LLCBought 18,931 shares on 2/15/2024Ownership: 0.020%View All Insider TransactionsView All Institutional Transactions HUMA Stock Analysis - Frequently Asked Questions Should I buy or sell Humacyte stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Humacyte in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" HUMA shares. View HUMA analyst ratings or view top-rated stocks. What is Humacyte's stock price target for 2024? 4 Wall Street research analysts have issued twelve-month price objectives for Humacyte's stock. Their HUMA share price targets range from $4.00 to $15.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 158.1% from the stock's current price. View analysts price targets for HUMA or view top-rated stocks among Wall Street analysts. How have HUMA shares performed in 2024? Humacyte's stock was trading at $2.84 at the beginning of 2024. Since then, HUMA shares have increased by 9.2% and is now trading at $3.10. View the best growth stocks for 2024 here. Are investors shorting Humacyte? Humacyte saw a decline in short interest in March. As of March 15th, there was short interest totaling 3,780,000 shares, a decline of 36.5% from the February 29th total of 5,950,000 shares. Based on an average trading volume of 870,900 shares, the days-to-cover ratio is presently 4.3 days. Currently, 4.5% of the company's shares are short sold. View Humacyte's Short Interest. When is Humacyte's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our HUMA earnings forecast. How were Humacyte's earnings last quarter? Humacyte, Inc. (NASDAQ:HUMA) posted its quarterly earnings data on Friday, March, 22nd. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.25) by $0.01. During the same period in the prior year, the company earned ($0.21) EPS. What ETFs hold Humacyte's stock? ETFs with the largest weight of Humacyte (NASDAQ:HUMA) stock in their portfolio include Clough Select Equity ETF (CBSE).Clough Long/Short Equity ETF (CBLS). Who are Humacyte's major shareholders? Humacyte's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (3.02%), Vanguard Group Inc. (3.02%), Northern Trust Corp (0.55%), Charles Schwab Investment Management Inc. (0.47%), GSA Capital Partners LLP (0.42%) and United Asset Strategies Inc. (0.21%). Insiders that own company stock include Brady W Dougan, Dale A Sander, Heather Ledbetter Prichard, Laura E Niklason, Michael T Constantino and William John Scheessele. View institutional ownership trends. How do I buy shares of Humacyte? Shares of HUMA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:HUMA) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisorySHOCKING Footage From Tesla Gigafactory In Austin, TexasInvestorPlaceBuy this small stock before coming AI Tidal WaveChaikin AnalyticsThe 3rd Revolution in WarfareWeiss RatingsIs AI Energy Really 4 Million Times More Powerful Than Oil? (Surprising Answer)Banyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Humacyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.